Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
BACKGROUND
Cardiovascular disease (CVD) is leading cause of death in patients on renal replacement therapy. Increased concentration of fibrinogen, dyslipidemia, and impaired fibrinolysis are regarded as important risk factors for CVD. Intima media thickness (IMT) of the common carotid artery is related to coronary and cerebrovascular arterial disease. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a recently discovered inhibitor of the fibrinolytic system. The aim of study was to evaluate whether IMT is related to the hemostatic factors prothrombin fragments 1+2 (F 1+2), thrombin-antithrombin (TAT) complexes, plasmin-antiplasmin (PAP) complexes, fibrinogen, euglobulin clot lysis time (ECLT), TAFI, and thrombomodulin in peritoneally dialyzed (PD) and hemodialyzed (HD) patients.


METHODS
The study included 80 chronically dialyzed patients (27 on PD, 53 on HD). The hemostatic parameters were measured with commercially available kits.


RESULTS
Significant positive correlations were found between fibrinogen or triglycerides and TAFI activity only in the PD patients. In univariate analysis, IMT correlated significantly with age, cholesterol, CRP, fibrinogen, hemoglobin, prothrombin time, activated partial thromboplastin time, and iron in the PD patients. In multiple regression analysis, IMT was only independently related to age and cholesterol in PD patients. In HD patients, IMT correlated with age, prothrombin time, and iron and in multiple regression analysis IMT was only independently related to age.


CONCLUSIONS
The correlations between IMT and Hb may imply a role of these rheological factors in the progression and acceleration of arterial remodeling in the PD population. Age remains the most significant predictor of IMT in both dialyzed populations
Małyszko
Jolanta
J
Department of Nephrology, Medical University, Białystok, Poland. jolmal@poczta.onet.pl
Łebkowska
Urszula
U
Małyszko
Jacek S
JS
Myśliwiec
Michał
M
D000328:Adult; D000368:Aged; D000990:Antithrombin III; D050197:Atherosclerosis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000473:pathology; D002339:Carotid Arteries / Q000473:pathology*; D016022:Case-Control Studies; D005260:Female; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D011516:Prothrombin; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D017539:Tunica Intima / Q000473:pathology; D055815:Young Adult
D015415:Biomarkers; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases